PPuubblliisshheedd OOnnlliinneeFFiirrsstt OOccttoobbeerr 2288,, 22001133;; DDOOII:: 1100..11115588//11005555--99996655..EEPPII--1133--11004411
No Link between Breast Cancer and Meningioma: Results from a
Large Monoinstitutional Retrospective Analysis
Carmen Criscitiello, Davide Disalvatore, Michele Santangelo, et al.
Cancer Epidemiol Biomarkers Prev 2014;23:215-217. Published OnlineFirst October 28, 2013.
Updated version Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-13-1041
E-mail alerts Sign up to receive free email-alerts related to this article or journal.
Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department
Subscriptions atpubs@aacr.org.
Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at
permissions@aacr.org.
DDoowwnnllooaaddeedd ffrroomm cceebbpp..aaaaccrrjjoouurrnnaallss..oorrgg oonn OOccttoobbeerr 2288,, 22001144.. ©© 22001144 AAmmeerriiccaann AAssssoocciiaattiioonn ffoorr CCaanncceerr RReesseeaarrcchh..
Published OnlineFirst October 28, 2013; DOI: 10.1158/1055-9965.EPI-13-1041
Cancer
Epidemiology,
Null Results in Brief Biomarkers
&Prevention
No Link between Breast Cancer and Meningioma: Results
from a Large Monoinstitutional Retrospective Analysis
CarmenCriscitiello1,2,DavideDisalvatore3,MicheleSantangelo4,NicoleRotmensz3,BarbaraBazolli3,
PatrickMaisonneuve3,AronGoldhirsch1,andGiuseppeCurigliano1,2
Abstract
Background:Theetiologyofmeningiomaislargelyunknown,althoughbreastcancerhasbeensuggestedto
playarole.
Methods:Amonoinstitutional,retrospectiveanalysiswasperformedatEuropeanInstituteofOncologyon
12,330patientswithbreastcancer.ThecumulativeincidenceofmeningiomawasestimatedusingtheKaplan–
Meiermethodandthelog-ranktestwasusedtoassessdifferencesbetweengroups.
Results:Intotal,33patientswithmeningiomawereidentifiedfromastudypopulationof12,330,witha10-
year cumulative incidence of meningioma of 0.37%. We did not find a significantly increased risk of
meningiomaamongpatientswithbreastcanceroranassociationbetweenthehormonalreceptorstatusand
theriskofmeningioma(P¼0.65).
Conclusions:Ourresultsdonotsupportaroleofbreastcancerorendocrinetreatmentsinmeningioma
development.
Impact:Thisanalysisaddsnewinformationonadebatedtopic.CancerEpidemiolBiomarkersPrev;23(1);
215–7. (cid:1)2013 AACR.
Introduction crine-responsivetumorstofindapotentiallinkbetween
thesetumorsandendocrinetherapy.
Meningiomasaretypicallybenigntumorsarisingfrom
themeningothelialcellsofthearachnoidmembranecov-
Materials and Methods
eringthebrainandspinalcord.Theetiologyofmeningi-
omas is largely unknown. There is evidence to suggest Datafrom12,330womenwithearly-stagebreastcancer
thatbreastcancermayplayaroleinthedevelopmentof who underwent surgery at the European Institute of
meningiomas, including the observation that these Oncology (IEO) in Milan between 1994 and 2011 were
tumors occur more commonly in women (1, 2). Further retrieved from two institutional databases: the Breast
evidenceforapossibleroleforhormonesinbraintumor Cancerdatabase,whichcontainsinformationonpatients
etiology includes the presence of progesterone (PgR), withbreastcanceroperatedatIEO,andtheTumorReg-
estrogen(ER),andandrogenreceptorsinsomemeningi- istry. Patients who received neoadjuvant treatment,
omas,suggestingalinkbetweenbreastcancerandmenin- patients with a previous history of cancer, or patients
giomas. Immunohistochemical studies have shown that withmetastaticbreastcanceratdiagnosiswereexcluded
about70%ofmeningiomasexpress PgRandabout30% from the analysis. Breast cancer–related data on age,
expressER,thuscorroboratingthehypothesisthatmenin- menopausal status, surgery, histopathology (Ki-67
giomaisahormone-sensitivetumor(3,4).Ourstudywas expression, ER/PgR expression, and HER2 status) and
carried out to explore the possible association between systemictreatmentwereanalyzed.Usually,patientswere
breast cancer, endocrine therapy, and the risk of devel- followedupwithphysicalexaminationevery6months,
opingmeningiomainalargemonoinstitutionalpopula- annualmammography,breastultrasound,andbloodtests
tionofpatientswithbreastcancer.Wefocusedonendo- every 6 to 12 months, and additional evaluations when
clinicallyindicated.Wheneverpossible,thehealthstatus
ofwomenwhodidnotcomebackforscheduledfollow-up
Authors'Affiliations: 1BreastCancerProgram,2DivisionofEarlyDrug
Development,3DivisionofEpidemiologyandBiostatistics,EuropeanInsti- visitsformorethan1yearwasobtainedbyphonecontact.
tute of Oncology, Milan; and 4Department of Advanced Biomedical Institutional Review Board approved this retrospective
Sciences,OperativeUnitofGeneralSurgeryandTransplants,University analysis.Theprimaryendpointwasthecumulativeinci-
NaplesFedericoII,Napoli,Italy
dence of meningioma (cum-inc ME), calculated from
CorrespondingAuthor:CarmenCriscitiello,DivisionofEarlyDrugDevel-
breastsurgerytomeningiomadiagnosis.Thecum-incME
opment,IstitutoEuropeodiOncologia,ViaRipamonti435,20141,Milano,
Italy.Phone:39-0294-3742-689;Fax:39-0294-379-224;E-mail: wasestimatedusingtheKaplan–Meiermethod.Thelog-
carmen.criscitiello@ieo.it ranktestwasusedtoassessdifferencesbetweengroups.
doi:10.1158/1055-9965.EPI-13-1041 AllanalyseswerecarriedoutwiththeSASsoftware9.3
(cid:1)2013AmericanAssociationforCancerResearch. (SASInstitute).
www.aacrjournals.org 215
Downloaded from cebp.aacrjournals.org on October 28, 2014. © 2014 American Association for Cancer Research.
Published OnlineFirst October 28, 2013; DOI: 10.1158/1055-9965.EPI-13-1041
Criscitielloetal.
Table 1. Association between patients' characteristics and meningioma
Numberof
meningioma 10-yearcumulative
Variable All(%column) (%row) incidence(95%CI) P
Number 12,330(100) 33(0.3) 0.37(0.26–0.55)
Ageatsurgery 0.24
<35 514(4.2) 0(0.0) 0.00(0.00–0.00)
35–50 5,005(40.6) 13(0.3) 0.38(0.21–0.70)
51–65 4,728(38.3) 12(0.3) 0.29(0.16–0.53)
>65 2,083(16.9) 8(0.4) 0.73(0.32–1.65)
ER 0.18
ER¼0 1,722(14.0) 7(0.4) 0.59(0.23–1.49)
ER>0 10,608(86.0) 26(0.2) 0.34(0.22–0.51)
PgR 0.60
PgR¼0 3,015(24.5) 7(0.2) 0.25(0.11–0.55)
PgR>0 9,315(75.5) 26(0.3) 0.42(0.27–0.64)
ER/PgR 0.65
Notexpressed(Both0) 1,655(13.4) 5(0.3) 0.28(0.11–0.75)
Expressed(ER>0orPgR>0) 10,675(86.6) 28(0.3) 0.38(0.25–0.58)
HER2 0.08
Notexpressed 9,557(77.5) 21(0.2) 0.36(0.23–0.56)
Intenseandcomplete 1,655(13.4) 8(0.5) 0.51(0.24–1.08)
Ki-67 0.32
<14% 3,416(27.7) 11(0.3) 0.44(0.24–0.83)
(cid:2)14% 8,902(72.2) 21(0.2) 0.33(0.20–0.54)
Subtype2013
LUMAPgR>20% 2,405(19.5) 8(0.3) 0.56(0.27–1.12) 0.08
LUMBKi-67(cid:2)14%orPgR(cid:3)20% 7,183(58.3) 15(0.2) 0.33(0.19–0.57)
LUMBHER2POS 1,086(8.8) 4(0.4) 0.38(0.12–1.19)
HER2þ 630(5.1) 4(0.6) 0.71(0.27–1.88)
TN 1,024(8.3) 0(0.0) 0.00(0.00–0.00)
Menopausalstatus 0.08
Premenopausal 5,769(46.8) 11(0.2) 0.28(0.14–0.55)
Postmenopausal 6,561(53.2) 22(0.3) 0.46(0.29–0.72)
Hormonetherapyperformed 0.53
No 2,061(16.7) 7(0.3) 0.35(0.16–0.79)
Yes 9,947(80.7) 26(0.3) 0.38(0.25–0.59)
Hormonetherapy 0.054
Tamoxifen 7,037(75.2) 17(0.2) 0.31(0.18–0.52)
Aromataseinhibitor 2,315(24.8) 7(0.3) 0.74(0.32–1.72)
Chemotherapy 0.98
No 7,099(57.6) 18(0.3) 0.35(0.21–0.57)
Yes 4,932(40.0) 15(0.3) 0.41(0.23–0.73)
CT/HT 0.66
Nil 509(4.1) 3(0.6) 0.75(0.24–2.31)
ET 6,520(52.9) 15(0.2) 0.32(0.19–0.55)
CT 1,521(12.3) 4(0.3) 0.22(0.07–0.69)
ET-CT 3,384(27.4) 11(0.3) 0.47(0.24–0.90)
Abbreviations:ET,endocrinetherapy;CT,chemotherapy;HT,hormonetherapy;TN,triple-negative.
Results
meningiomawereidentifiedfromastudypopulationof
FromJanuary1994toDecember2011,weidentifieda 12,330.Table 1describes selecteddemographic, clinical,
totalof12,330consecutivepatientswithearly-stagebreast andpathologiccharacteristicsofthestudypopulationat
cancer.Atamedianfollow-upof7years,33patientswith the time of breast cancer surgery, systemic treatments
216 CancerEpidemiolBiomarkersPrev;23(1)January2014 CancerEpidemiology,Biomarkers&Prevention
Downloaded from cebp.aacrjournals.org on October 28, 2014. © 2014 American Association for Cancer Research.
Published OnlineFirst October 28, 2013; DOI: 10.1158/1055-9965.EPI-13-1041
BreastCancerandMeningioma
administered,numberofmeningiomas,and10-yearcum- Despitethelargecohort,amajorlimitationofthisstudyis
inc ME. Considering the entire population, the 10-year the small number of meningioma cases recorded with
cum-inc ME was 0.37% [95% confidence interval (CI), exposure to endocrine therapy. However, it has to be
0.26%–0.55%]. No association was found between ER/ acknowledgedthatthescreeningformeningiomaisnot
PgR and the risk of meningioma. No association was routinelyconductedinpatientswithbreastcancer.Also,
found if we matched analysis coupling ER and PgR (P theendocrinetherapygiventoER-positivepatientsmay
¼0.65)orconsideringthemseparately(ER,P¼0.18and haveinfluencedthedevelopmentofmeningiomaduring
PgR,P¼0.60).Patientswhoreceivedaromataseinhibitors thisperiod.Anotherlimitationisrelatedtotheretrospec-
had a trend of higher risk to develop meningioma tiveanalysis.Animportantstrengthisthattherecordsof
compared with patients who received tamoxifen, with potential cases were manually reviewed and the case
aborderlinestatisticalsignificance(P¼0.054).Noother status was validated by a data-monitoring system with
significant association was observed in the analyzed a confirmation rate of 100%. In summary, this study, in
variables. contrastwithpreviouscohortstudies,foundnoassocia-
tion between development of meningioma and breast
Discussion
cancer.
This large, retrospective study evaluated more than
12,000 patients with breast cancer with an average fol- DisclosureofPotentialConflictsofInterest
low-up period of 7 years, and identified a total of 33 Nopotentialconflictsofinterestweredisclosed.
individualswithanincidentcaseofmeningioma.There
was no significant association between meningioma
Authors'Contributions
developmentandbreastcancer.Useofaromataseinhibi-
Conceptionanddesign:C.Criscitiello,D.Disalvatore,M.Santangelo,
torsconferredatrendofincreasedriskofmeningiomain N.Rotmensz,P.Maisonneuve,G.Curigliano
patientswithbreastcancer,althoughnostatisticalsignif- Developmentofmethodology:C.Criscitiello,D.Disalvatore,M.Santan-
gelo,G.Curigliano
icancewasobserved.Thelinkbetweenbreastcancerand Acquisitionofdata(providedanimals,acquiredandmanagedpatients,
meningiomahasbeenreportedinliterature,withdiscor- provided facilities, etc.): C. Criscitiello, D. Disalvatore, N. Rotmensz,
G.Curigliano
dant results. What is behind this association is quite
Analysisandinterpretationofdata(e.g.,statisticalanalysis,biostatis-
unclear,mostlikelybeingahormonaletiology.Hormone tics,computationalanalysis):C.Criscitiello,D.Disalvatore,M.Santan-
receptorsareinvolvedinbothtumortypes.Inmeningi- gelo,N.Rotmensz,A.Goldhirsch,G.Curigliano
Writing,review,and/orrevisionofthemanuscript:C.Criscitiello,D.
omas,PgRismoreprevalentandmorebiologicallyactive
Disalvatore,M.Santangelo,P.Maisonneuve,A.Goldhirsch,G.Curigliano
thanER.Toascertainalinkbetweenhormonalexposure Administrative,technical,ormaterialsupport(i.e.,reportingororga-
and development of meningioma, we focused on endo- nizingdata,constructingdatabases):C.Criscitiello,D.Disalvatore,N.
Rotmensz,B.Bazolli
crine-responsivebreastcancerandonpatientsreceiving Studysupervision:C.Criscitiello,M.Santangelo,G.Curigliano
endocrinetherapy.Inourcohort,the10-yearcum-incME
was0.37%(95%CI,0.26–0.55),similartothatreportedby
Received October 9, 2013; accepted October 17, 2013; published
Raoandcolleagues(1).Ourstudyhasseverallimitations. OnlineFirstOctober28,2013.
References
1. RaoG,GiordanoSH,LiuJ,McCutcheonIE.Theassociationofbreast 3. Carroll RS, Zhang J, Black PM. Expression of estrogen receptors
cancerandmeningiomainmenandwomen.Neurosurgery2009;65: alpha and beta in human meningiomas. J Neurooncol 1999;42:
483–9. 109–16.
2. Schoenberg BS, Christine BW, Whisnant JP. Nervous system neo- 4. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen
plasmsandprimarymalignanciesofothersites.Theuniqueassociation receptors in meningiomas: prognostic considerations. J Neurosurg
betweenmeningiomasandbreastcancer.Neurology1975;25:705–12. 1997;86:113–20.
www.aacrjournals.org CancerEpidemiolBiomarkersPrev;23(1)January2014 217
Downloaded from cebp.aacrjournals.org on October 28, 2014. © 2014 American Association for Cancer Research.
